Baker Heart and Diabetes Institute (External organisation)

Activity: Industry, Government and Philanthropy Engagement and PartnershipsConsultancy


Patient characteristics and cardiovascular and mortality outcomes in patients with high cardiovascular risk and type 2 diabetes mellitus initiating treatment with sodium-glucose co-transporter-2 inhibitors and other antidiabetic medications, as per the project proposal in accordance with the Study Protocol (annexed at Annexure 1 to the Funding Agreement) (“Project”).
Period1 Aug 201715 Feb 2018
Held atBaker Heart and Diabetes Institute, Australia, Victoria
Degree of RecognitionNational